VITASPRING BIOMEDICAL CO., LTD. (VSBC) Total liabilities 2017–2026
VITASPRING BIOMEDICAL CO., LTD. (VSBC) total liabilities at each fiscal year-end, per SEC filings.
$4.4MFY2026 · since FY2017: $4,555 → $4.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $4.4M | +10.3% |
| FY2025 | $4.0M | +15.5% |
| FY2024 | $3.5M | +10.3% |
| FY2023 | $3.2M | +56.1% |
| FY2022 | $2.0M | +2078.3% |
| FY2021 | $93,034 | -3.5% |
| FY2020 | $96,364 | +743.0% |
| FY2019 | $11,431 | -11.3% |
| FY2018 | $12,891 | +183.0% |
| FY2017 | $4,555 | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice
More VSBC financial trends
VSBC RevenueVSBC Net incomeVSBC Net marginVSBC Gross profitVSBC Gross marginVSBC Operating incomeVSBC Operating marginVSBC Operating cash flowVSBC Free cash flowVSBC Capital expendituresVSBC Return on equityVSBC Stock buybacksVSBC Dividends paidVSBC Total assetsVSBC Shareholders’ equityVSBC overview →